The incidence of Ductal Carcinoma In Situ (‘DCIS’ or Stage 0 disease) markedly increased from 5.8 per 100,000 women in the 1970s to 32.5 per 100,000 women in 2004 and has since reached a plateau. Around 25% of breast cancers diagnosed in the United States are DCIS, and 55,720 new cases have been reported in 2023. This increase is attributed primarily to the utilization of breast cancer screening by mammography [1].
According to ESMO Guidelines Breast Cancer Surgery with post-operative RT is the preferred local treatment option for the majority of patients with early breast cancer [2].
There is an opportunity for YntraDose to provide an alternative to Intra-Operative Radiotherapy (IORT) and post-surgery SBRT for the effective treatment of surgical margins. YntraDose can be directly implanted into the tumour bed following tissue conserving lumpectomy prior to surgically closing the patient.
YntraDopse can confer several advantages over IORT or EBRT in this setting, including reduced patient visits, improved patient compliance, no capital equipment and operational and resource efficiency savings for healthcare providers.